Negev Labs is advancing a pipeline of human-validated serotonin agonists designed for de-risked development in high unmet need neuropsychiatric indications. Our lead program AB-300, a non-hallucinogenic 5-HT2A/2C agonist, is progressing through IND-enabling work with Phase Ib in Parkinson’s disease patients targeted for mid 2026 and key readouts in 2027. Meanwhile we are advancing potent 5-HT1B agonists which have demonstrated robust preclinical efficacy on the reduction of aggression without overt sedation. Development candidate nomination is expected in early 2026 after confirmatory studies and pharmacology assessments. Ultimately, we aim to develop this series of compounds for agitation associated with Alzheimer's disease.